The FDA has told Regeneron to hit the brakes on its experimental blood cancer drug trial over safety concerns.

Digital pathology developer Paige has received two European approvals for its artificial-intelligence-powered diagnostic platforms in breast and prostate cancers.

Acutus Medical has received two CE marks this week for heart treatment devices and access tools and has begun their European commercial launch.

Most approaches to preventing heart attacks focus on ameliorating risk factors like high cholesterol or high blood pressure. But what if heart attacks could be prevented altogether by targeting genes that raise the risk of coronary artery disease?

TAIPEI and SAN DIEGO — Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, announced their Abstract on Cholangiocarcinoma treatment with Silmitasertib (CX-4945) has been accepted for oral/poster presentation at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, 15-17 January, 2021. Due to the COVID-19 pandemic, the event will be hosted virtually.

Palbociclib is the standard of care for patients with advanced breast cancer, yet researchers still have no molecular profile to predict which patients will progress, which will continue benefitting from this therapy after their initial treatment, and which combination therapies are most effective. MEDSIR, a global company dedicated to independent oncology research, teased out this information in two studies presented recently at the San Antonio Breast Cancer Symposium.

Sanofi’s response to nonfatal thrombotic events in a phase 3 hemophilia program has delayed its plans to seek approval for RNAi drug fitusiran by 18 months. The delay will “allow for the appropriate collection and assessment of safety and efficacy data under the amended protocols.”

Israeli biotech Pluristem is canning its experimental phase 3 critical limb ischemia therapy after an outside review said it was no good.

Texas-based biotech Savara is killing off much of its pipeline work amid a staffing cull as it sets its focus on troubled lung disease therapy Molgradex.

Most approaches to preventing heart attacks focus on ameliorating risk factors like high cholesterol or high blood pressure. But what if heart attacks could be prevented altogether by targeting genes that raise the risk of coronary artery disease?